TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04502537

Intervention type: DRUG
Intervention: Roxadustat
Description: Oral

Intervention type: DRUG
Intervention: erythropoietin
Description: injection
Study: NCT05716074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Description: The supervised group will be given 10 minutes of warm-up, 10 minutes of breathing exercises, 20 minutes of low endurance combined exercises (stretching, strengthening, strength exercises), 10 minutes of balance and walking training, and 10 minutes of cool-down exercises. Exercise will be applied for 1 hour a day, 3 days a week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise
Description: The home group will be given 10 minutes of warm-up, 10 minutes of breathing exercises, 20 minutes of low endurance combined exercises (stretching, strengthening, strength exercises), 10 minutes of balance and walking training, and 10 minutes of cool-down exercises. Exercise will be applied for 1 hour a day, 3 days a week for 6 weeks in the home.
Study: NCT05612308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vertical Oscillatory Pressure (VOP)
Description: The VOP involves a pressure from the posterior aspect of the body while patient lye prone. the pressure is exacted directly on the spine, The sustained Natural Apophyseal Glides involves pressure as well when the patient sits down on a chair. The movement is done from the posterior to the anterior as well
Study: NCT04931693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: iv post operative analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modifiedPECs block
Description: sonar guided pectoral nerve block
Study: NCT06043401

Intervention type: OTHER
Intervention: Neuroimaging with Magnetic Resonance Imaging (MRI)
Description: MRI will be used to observe brain states over time.

Intervention type: OTHER
Intervention: Neuroimaging with Magnetic Resonance Imaging (MRI)
Description: MRI will be used to observe brain states over time.
Study: NCT05854355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C-SLAMM Study
Description: The intervention arm includes using innovative behavioural, pedagogical, and environmental strategies within the classroom, school, and home settings to get children moving more and sitting less. The strategies were based on strategies used in Transform-Us! involved incorporating movement into everyday class lessons - the delivery of the lesson changes, not the content. Resources included health lessons, active lessons, active breaks, active homework to do with parents, active environments, and newsletters for parents.
Study: NCT04892264

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT06286995

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chemomechanical preparation for root canals
Description: After working length determination ,root canal preparation was made by two different NiTi File systems to both group ( the first group using Trunatomy file and the second one using edgeendo x7 file) and assessment of pain was made preoperatively and postoperatively and also apical fluid samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chemomechanical preparation for root canals
Description: After working length determination ,root canal preparation was made by two different NiTi File systems to both group ( the first group using Trunatomy file and the second one using edgeendo x7 file) and assessment of pain was made preoperatively and postoperatively and also apical fluid samples
Study: NCT04892264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skeletal Survey X-Ray
Description: Undergo X-ray skeletal survey

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skeletal Survey X-Ray
Description: Undergo X-ray skeletal survey

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Dose Computed Tomography of the Whole Body
Description: Undergo whole body low dose CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Dose Computed Tomography of the Whole Body
Description: Undergo whole body low dose CT
Study: NCT06566547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR1803 injection
Description: D1 given at a dose of 30ug/kg, D4 given at a dose of 90ug/kg, D8 given at a dose of 180ug/kg, followed by weekly dosing up to cycle 9, and cycle 10 and onwards, every 2 weeks, with a dosing cycle of every 4 weeks
Study: NCT04892264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study: NCT06333379

Intervention type: OTHER
Intervention: Compare the levels of Galactomannan (GM) levels in exhaled breath condensate (EBC) and BALF
Description: Investigators tested EBC-GM levels and BALF-GM levels in patients with confirmed IPA to compare the diagnostic value of EBC-GM versus BALF-GM.

Intervention type: OTHER
Intervention: Compare the levels of Galactomannan (GM) levels in exhaled breath condensate (EBC) and BALF
Description: Investigators tested EBC-GM levels and BALF-GM levels in patients with confirmed IPA to compare the diagnostic value of EBC-GM versus BALF-GM.
Study: NCT05580432

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parenting with Positive Behavior Interventions
Description: Parenting with Positive Behavior Interventions is a 5 month packaged intervention. The curriculum and each element of the training and coaching program is described in detail below.~Each month, participants will participate in the following five activities:~1. Didactic Training: Participants will view a presentation~2. Workbook/Homework: Participants will complete a guided worksheet~3. Coaching Meeting - Planning: Participants will meet with a coach who is an expert in autism and behavior~4. Coaching - Observation/ Feedback: The coach will observe parent implementing the strategy, then provide feedback and direction regarding use of technique~5. Virtual Parent Community of Support Meeting: Attend parent led community support meeting to network, share experiences and information, and exchange ideas
Study: NCT05774639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab Injection
Description: ADL-018 (Omalizumab) solution for injection 150 mg/mL prefilled syringe (PFS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab Injection
Description: ADL-018 (Omalizumab) solution for injection 150 mg/mL prefilled syringe (PFS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab Injection
Description: ADL-018 (Omalizumab) solution for injection 150 mg/mL prefilled syringe (PFS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab Injection
Description: ADL-018 (Omalizumab) solution for injection 150 mg/mL prefilled syringe (PFS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab Injection
Description: ADL-018 (Omalizumab) solution for injection 150 mg/mL prefilled syringe (PFS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab Injection
Description: ADL-018 (Omalizumab) solution for injection 150 mg/mL prefilled syringe (PFS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xolair Prefilled Syringe
Description: XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xolair Prefilled Syringe
Description: XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xolair Prefilled Syringe
Description: XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xolair Prefilled Syringe
Description: XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xolair Prefilled Syringe
Description: XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xolair Prefilled Syringe
Description: XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution
Study: NCT05607524

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: Eat a capsule for once, and twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Eat a capsule for once, and twice a day
Study: NCT05549011

Intervention type: OTHER
Intervention: PENG Block
Description: PENG block for analgesic purposes performed before hip surgery

Intervention type: OTHER
Intervention: SIFI compartment block
Description: SIFI compartment block for analgesic purposes performed before hip surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: Numeric Rating Scale
Description: Self-reported pain intensity score between 0-10

Intervention type: DIAGNOSTIC_TEST
Intervention: Numeric Rating Scale
Description: Self-reported pain intensity score between 0-10

Intervention type: DIAGNOSTIC_TEST
Intervention: Angle of sitting
Description: Measurement of sitting angle in degrees with a protractor

Intervention type: DIAGNOSTIC_TEST
Intervention: Angle of sitting
Description: Measurement of sitting angle in degrees with a protractor
Study: NCT05906862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-253
Description: Administered intravenously
Study: NCT05580432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting with Positive Behavior Interventions
Description: Parenting with Positive Behavior Interventions is a 5 month packaged intervention. The curriculum and each element of the training and coaching program is described in detail below.~Each month, participants will participate in the following five activities:~1. Didactic Training: Participants will view a presentation~2. Workbook/Homework: Participants will complete a guided worksheet~3. Coaching Meeting - Planning: Participants will meet with a coach who is an expert in autism and behavior~4. Coaching - Observation/ Feedback: The coach will observe parent implementing the strategy, then provide feedback and direction regarding use of technique~5. Virtual Parent Community of Support Meeting: Attend parent led community support meeting to network, share experiences and information, and exchange ideas
Study: NCT06586658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD70-CAR-T cells
Description: The subjects received infusions of anti-CD70 CART cells following completion of lymphodepleting preconditioning chemotherapy. Dosage: 3×10\^6 cells/Kg; 1×10\^7 cells/Kg; 2×10\^7 cells/Kg.
Study: NCT06355180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subanesthetic dose intravenous esketamine
Description: The study, lasting 12 weeks, includes a 2-week intervention and 10-week follow-up. Esketamine (0.2mg/kg) is given intravenously three times a week for two weeks. Dosage and sessions may adjust for safety and efficacy, with study treatments limited during follow-up.~Efficacy is evaluated via scales measuring suicidal ideation, depression, cognition, and social function. Adverse effects are tracked through vital signs, exams, events, and tests.~Biological samples (blood, urine, feces) are collected from some participants at baseline, post-first, and sixth treatments for omics analyses.~Brain imaging from some participants at baseline and post-sixth treatment aims to obtain high-resolution T1, T2 FLAIR, resting fMRI, and DTI images.~Electrophysiological data, including resting state EEG signals and task paradigms, are collected from some participants at baseline, after the first, and sixth treatments.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified electroconvulsive therapy
Description: The study, lasting 12 weeks, includes a 2-week intervention and 10-week follow-up. Modified electroconvulsive therapy (MECT) is given three times a week for two weeks. Sessions may adjust for safety and efficacy, with study treatments limited during follow-up.~Efficacy is evaluated via scales measuring suicidal ideation, depression, cognition, and social function. Adverse effects are tracked through vital signs, exams, events, and tests.~Biological samples (blood, urine, feces) are collected from some participants at baseline, post-first, and sixth treatments for omics analyses.~Brain imaging from some participants at baseline and post-sixth treatment aims to obtain high-resolution T1, T2 FLAIR, resting fMRI, and DTI images.~Electrophysiological data, including resting state EEG signals and task paradigms, are collected from some participants at baseline, after the first, and sixth treatments.
Study: NCT06651203

Intervention type: OTHER
Intervention: Follow-up
Description: Clinical evaluation Blood sample Skin biopsy
Study: NCT06653374

Intervention type: BEHAVIORAL
Intervention: Infant, Premature
Description: This intervention is distinct as it focuses specifically on observational monitoring and evaluation of neonatal outcomes without applying a therapeutic or procedural treatment. Unlike other interventional studies, the emphasis is on analyzing standard care practices, risk factor exposures (e.g., prematurity, maternal complications), and their impact on neonatal morbidity and mortality. The intervention involves systematic data collection and longitudinal follow-up to identify patterns and associations, rather than introducing new clinical techniques or treatment

Intervention type: BEHAVIORAL
Intervention: Infant, Premature
Description: This intervention is distinct as it focuses specifically on observational monitoring and evaluation of neonatal outcomes without applying a therapeutic or procedural treatment. Unlike other interventional studies, the emphasis is on analyzing standard care practices, risk factor exposures (e.g., prematurity, maternal complications), and their impact on neonatal morbidity and mortality. The intervention involves systematic data collection and longitudinal follow-up to identify patterns and associations, rather than introducing new clinical techniques or treatment
Study: NCT06651762

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unilateral Radiofrequency
Description: unilateral genicular nerve cooled radio frequency ablation pre-operative

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral Radiofrequency
Description: bilateral genicular nerve cooled radio frequency ablation pre-operative

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural
Description: Patients will receive epidural anesthesia intra operative and epidural analgesia post-operative

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural
Description: Patients will receive epidural anesthesia intra operative and epidural analgesia post-operative
Study: NCT06479109

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivational materials for pregnant women attending antenatal care visits to improve supplement adherence
Description: During the antenatal care visit, pregnant women will receive the information sheet used by the provider and a dangler/poster to hang in a visible location in the participant's house. This will serve as a reminder for her and her family to take the daily pill.

Intervention type: OTHER
Group type: OTHER
Intervention: Providers
Description: Providers in intervention sites use an information sheet that serves as a job aid to counsel women about the benefits of the supplements. The sheet also includes adherence tips, such as involving family to increase adherence. The information sheet is provided to the woman to take home.~Antenatal care providers will use an information sheet describing the supplement's benefits and adherence tips to help pregnant women take IFAS or MMS.
Study: NCT06641856

Intervention type: OTHER
Intervention: Sample Collection
Description: All participants will provide nasal and pharyngeal swabs for virome analysis. A subset of 30 elderly volunteers will also provide peripheral blood samples and undergo bronchoscopy under general anesthesia to collect upper and lower respiratory tract samples.

Intervention type: OTHER
Intervention: Sample Collection
Description: All participants will provide nasal and pharyngeal swabs for virome analysis. A subset of 30 elderly volunteers will also provide peripheral blood samples and undergo bronchoscopy under general anesthesia to collect upper and lower respiratory tract samples.
Study: NCT06499701

Intervention type: DRUG
Intervention: Ringer's Lactate
Description: Ringer's Lactate is administered at a dose of 30ml/kg, with the first 20ml/kg given at a constant rate over the initial 30 minutes, followed by a 30-minute pause, and then an additional 10ml/kg over the next 15 minutes, completing the infusion within 75 minutes.
Study: NCT05027308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Teduglutide 0.05 mg/kg SC injection
Study: NCT04516122

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Intervention: Dual X-ray Absorptiometry
Description: Undergo DXA scan
Study: NCT04958694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CEDARS
Description: This intervention is intended to help adolescents cope with stress and improve positive affect.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CEDARS
Description: This intervention is intended to help adolescents cope with stress and improve positive affect.
Study: NCT05388942

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual reality hypnosis
Description: VRH offers predefined hypnosis sessions with no need of trained physician or nurse or caregiver mobilization. Consisting of a headset including headphones and a virtual reality screen, VRH allow patients to select a visual and sound environment (e.g.: tropical beach, space, underwater...) into which the hypnotic speech is delivered. That way, the patient's attention is distracted and muscular relaxation is obtained, a major relaxation factor. HRV is simple, quick, and presumably safe.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide
Description: inhalation of NO usually used to help with ASD reduction but inhaled NO has safety and maintenance issues.
Study: NCT06651762

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural
Description: Patients will receive epidural anesthesia intra operative and epidural analgesia post-operative
Study: NCT06439979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RAYS Intervention
Description: Developmental baseball leagues will be randomly assigned to RAYS vs. control. Outcomes include directly-observed child sun safety behaviors after controlling for environmental ultra-violet radiation (UVR), with parent-reported child sun protection and other related endpoints at 1 year.
Study: NCT04971564

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling will be made to Day 0, Day 3 and to 3 month after inclusion

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling will be made to Day 0, Day 3 and to 3 month after inclusion
Study: NCT06007014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiglitazar sodium
Description: tablets 48mg/ day administered for 18 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chiglitazar placebo
Description: tablets 48mg/ day administered for 18 weeks
Study: NCT05614245

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-2901e
Description: Intramuscular injection of VBI-2901e, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate and E6020 adjuvants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-2901e
Description: Intramuscular injection of VBI-2901e, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate and E6020 adjuvants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-2901e
Description: Intramuscular injection of VBI-2901e, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate and E6020 adjuvants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-2901e
Description: Intramuscular injection of VBI-2901e, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate and E6020 adjuvants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-2901e
Description: Intramuscular injection of VBI-2901e, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate and E6020 adjuvants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-2901e
Description: Intramuscular injection of VBI-2901e, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate and E6020 adjuvants
Study: NCT05060393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy
Description: Mobile application, mindfulness-based therapy
Study: NCT04999631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Squaric Acid Dibutyl Ester
Description: Topical squaric acid dibutyl ester (SADBE) dissolved in ethanol at 0.2% concentration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol Solution
Description: Control